Sebastian Kaulitzki / Alamy Stock Photo

Explore our latest content

Biopharma Dealmakers brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities.

Browse Articles

  • News Feature |

    In the first of a new monthly digest, we highlight recent ‘business of science’ articles from Springer Nature research journals, magazines and supplements. This digest looks at the latest drugs approved by the US FDA and a $1bn antibody development deal, peeps into the Chan Zuckerberg Biohub, and offers advice to budding science entrepreneurs.

    • Raveena Bhambra
  • News Feature |

    Last year saw an uptick in medtech mergers and acquisitions values, whereas financing declined. This year is bringing new opportunities and challenges for the field as it responds to the demands of the coronavirus.

    • Maureen Riordan
    •  & Amanda Micklus
  • Advertisement Feature |

    By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.

    • Kineta, Inc.
  • Advertisement Feature |

    Using its MicroRx platform, 4D pharma is pioneering the development of an emerging class of therapeutics known as live biotherapeutic products to treat a range of indications from cancer and respiratory disease to neurodegeneration.

    • 4D Pharma PLC